The bill S.106 aims to extend the tenure of the Psychedelic Therapy Advisory Working Group, which was originally established in 2024 under Act and Resolves No. 126. The Working Group's purpose is to review existing research on the cost-benefit profile of psychedelics for mental health improvement and to make recommendations regarding the establishment of a state program for healthcare providers to administer psychedelics in therapeutic settings. The bill proposes to expand the membership of the Working Group and its scope, allowing it to monitor evolving research and programs across the country, particularly focusing on psilocybin-assisted therapy for conditions such as depression and anxiety in serious illness and end-of-life care.

The bill includes several key provisions, such as the creation of a diverse membership for the Working Group, which will consist of representatives from various health and medical organizations, as well as experts in psychedelic treatment. The Working Group is tasked with reviewing the latest research, monitoring laws in other states, and proposing a pilot project for psilocybin-assisted therapies. Additionally, the bill mandates that the Working Group submit a report with findings and recommendations by November 15, 2025, and it will cease to exist on January 1, 2026. The act will take effect upon passage.